Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best future stocks to buy for the next 5 years. On March 30, Alnylam Pharmaceuticals presented new clinical and real-world data at the American College of Cardiology’s Annual Scientific Session/ACC.26 regarding its cardiovascular portfolio. The findings highlight the benefits of vutrisiran, which is an RNAi therapeutic that silences transthyretin/TTR at the source, for patients with transthyretin-mediated amyloidosis with cardiomyopathy/ATTR-CM.

Data from the HELIOS-B analysis showed that vutrisiran improved health-related quality of life and functional outcomes, with treatment effects in older patients appearing comparable to those observed in individuals more than a decade younger. The presentation detailed vutrisiran’s efficacy across the disease spectrum, including those with advanced illness and diastolic dysfunction.

Regarding the hypertension pipeline, Alnylam shared pooled Phase 2 safety data for zilebesiran, an investigational RNAi therapeutic designed to provide continuous blood pressure control through biannual dosing. The results support the ongoing evaluation of zilebesiran in the ZENITH Phase 3 Cardiovascular Outcomes Trial, which was initiated in late 2025 to address cardiovascular risk reduction.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a biotechnology company that develops therapeutics based on ribonucleic acid interference. The company currently has a range of products in Phase 3, Phase 2, and Phase 1 trials.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.